TARS Earnings & Financial Statements
Tarsus Pharmaceuticals, Inc.
$71.13
-$2.48(-3.37%)
47
Overall
40
Value
45
Tech
57
Quality
Market Cap
$3.47B
Volume
146.76K
52W Range
$53.89 - $91.53
Target Price
$98.56
TARS earnings and financial statements: Tarsus Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TARS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $451.36M | $182.95M | $17.45M | $25.82M | $57.03M |
| Cost of revenue | $30.68M | $12.83M | - | - | $2.08M |
| Operating income | -$70.97M | -$120.57M | -$143.16M | -$62.71M | -$12.16M |
| EBITDA | -$53.02M | -$106.00M | -$135.69M | -$60.25M | -$13.46M |
| Net income | -$66.42M | -$115.55M | -$135.89M | -$62.09M | -$13.83M |
| EPS (diluted) | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $562.16M | $376.99M | $265.49M | $227.86M | $178.91M |
| Total liabilities | $218.73M | $152.46M | $68.50M | $34.96M | $12.18M |
| Shareholders’ equity | $343.43M | $224.53M | $196.99M | $192.90M | $166.73M |
| Cash and equivalents | $183.64M | $94.82M | $224.95M | $71.66M | $171.33M |
| Long-term debt | $72.44M | $71.84M | $29.82M | $19.43M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.45M | -$83.03M | -$117.49M | -$49.03M | $3.75M |
| Capital expenditure | -$9.86M | -$6.57M | -$5.50M | -$506.0K | -$586.0K |
| Free cash flow | -$22.31M | -$89.59M | -$123.00M | -$49.54M | $3.16M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TARS | $71.13 | -3.4% | 146.76K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Tarsus Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW